URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

David Davidson Biography and Net Worth

Insider of bluebird bio

David Davidson, M.D., is the former chief medical officer for Bluebird bio, a leading biotechnology company developing innovative gene therapies. He announced his departure from the company in March 2021, but will remain on as a consultant for six months to assist with the transition of his duties.

Dr. Davidson joined Bluebird as its CMO in 2012. He had previously spent eight years at Genzyme, serving as a senior medical director leading clinical research for programs across wide-ranging therapeutic areas. His most recent work was as the medical leader for the company’s gene therapy and Pompe disease enzyme replacement therapy (ERT) programs.

Throughout his career, Dr. Davidson has worked on various commercial products, such as Fabrazyme, Myozyme, and Lumizyme—all ERTs. He also played a key role in creating the new drug application resulting in the approval of cholesterol drug, Welchol.

Before Genzyme, he served as a medical director for GelTex Pharmaceuticals Inc.

Additionally, Dr. Davidson completed infectious disease fellowships through the Harvard Longwood Combined Infectious Diseases Program. He also completed an internal medicine internship, residency, and an endocrinology fellowship with the University of Chicago Hospitals.

Dr. Davidson earned his bachelor’s degree at Columbia University and his M.D. at the New York University School of Medicine.

What is David Davidson's net worth?: The estimated net worth of David Davidson is at least $16,872.50 as of October 2nd, 2020. Dr. Davidson owns 1,985 shares of bluebird bio stock worth more than $16,873 as of December 22nd. This net worth approximation does not reflect any other assets that Dr. Davidson may own. Learn More about David Davidson's net worth.
How do I contact David Davidson?: The corporate mailing address for Dr. Davidson and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at [email protected]. Learn More on David Davidson's contact information.
Has David Davidson been buying or selling shares of bluebird bio?: David Davidson has not been actively trading shares of bluebird bio during the last quarter. Most recently, David Davidson sold 3 shares of the business's stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $1,055.40, for a transaction totalling $3,166.20. Following the completion of the sale, the insider now directly owns 1,985 shares of the company's stock, valued at $2,094,969. Learn More on David Davidson's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 463 shares worth more than $9,849.60. The most recent insider tranaction occured on December, 10th when CEO Andrew Obenshain sold 48 shares worth more than $403.20. Insiders at bluebird bio own 1.4% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 12/10/2024.

David Davidson Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2020	Sell	3	$1,055.40	$3,166.20	1,985
7/2/2020	Sell	2	$1,231.40	$2,462.80	1,992
9/10/2019	Sell	102	$2,003.20	$204,326.40	1,730
7/5/2019	Sell	382	$2,589.40	$989,150.80	1,947
5/6/2019	Sell	317	$2,779.00	$880,943.00	1,898
4/4/2019	Sell	317	$3,201.20	$1,014,780.40	1,898
3/13/2019	Sell	154	$2,928.20	$450,942.80	1,735
3/4/2019	Sell	245	$3,115.40	$763,273.00	1,826
2/4/2019	Sell	245	$2,686.00	$658,070.00	1,580
1/18/2019	Sell	101	$2,601.00	$262,701.00	1,213
1/3/2019	Sell	379	$1,976.40	$749,055.60	777
12/4/2018	Sell	99	$2,421.00	$239,679.00	1,545
11/2/2018	Sell	249	$2,672.80	$665,527.20	1,495
10/2/2018	Sell	249	$2,786.40	$693,813.60	1,495
9/4/2018	Sell	349	$3,332.80	$1,163,147.20	1,595
7/11/2018	Sell	149	$3,603.00	$536,847.00	1,395
7/2/2018	Sell	499	$3,079.20	$1,536,520.80	1,745
6/4/2018	Sell	649	$3,756.80	$2,438,163.20	1,895
5/2/2018	Sell	649	$3,550.40	$2,304,209.60	1,895
4/12/2018	Sell	149	$3,603.40	$536,906.60	1,395
4/2/2018	Sell	1,099	$3,350.40	$3,682,089.60
2/2/2018	Sell	199	$4,047.20	$805,392.80
1/8/2018	Sell	176	$3,472.20	$611,107.20	697
1/3/2018	Sell	299	$3,606.00	$1,078,194.00	1,098
10/2/2017	Sell	199	$2,626.20	$522,613.80
8/1/2017	Sell	149	$1,847.40	$275,262.60	948
7/7/2017	Sell	59	$2,009.80	$118,578.20	803
7/5/2017	Sell	249	$2,105.60	$524,294.40	1,108
6/5/2017	Sell	49	$1,800.00	$88,200.00	908
4/3/2017	Sell	149	$1,817.80	$270,852.20	1,008
1/27/2017	Sell	299	$1,380.40	$412,739.60	733
7/15/2016	Sell	49	$901.60	$44,178.40	529
6/15/2016	Sell	49	$802.20	$39,307.80	529
5/16/2016	Sell	49	$774.60	$37,955.40	529
4/15/2016	Sell	49	$992.60	$48,637.40	529
3/15/2016	Sell	49	$922.60	$45,207.40	529
2/16/2016	Sell	49	$903.60	$44,276.40	49
1/15/2016	Sell	49	$887.80	$43,502.20
12/15/2015	Sell	49	$1,171.00	$57,379.00
11/16/2015	Sell	99	$1,419.80	$140,560.20
10/15/2015	Sell	99	$1,594.00	$157,806.00
9/15/2015	Sell	99	$2,599.60	$257,360.40
7/15/2015	Sell	99	$3,319.20	$328,600.80
6/15/2015	Sell	99	$3,666.80	$363,013.20
4/15/2015	Sell	99	$2,603.60	$257,756.40
3/2/2015	Sell	199	$1,896.80	$377,463.20
1/2/2015	Sell	199	$1,800.20	$358,239.80
12/8/2014	Sell	749	$922.00	$690,578.00
12/3/2014	Sell	149	$833.00	$124,117.00
11/3/2014	Sell	149	$833.60	$124,206.40
10/1/2014	Sell	149	$691.00	$102,959.00
9/2/2014	Sell	149	$760.00	$113,240.00
8/1/2014	Sell	149	$672.40	$100,187.60
7/1/2014	Sell	149	$791.00	$117,859.00
5/1/2014	Sell	199	$397.00	$79,003.00
1/3/2014	Sell	749	$417.60	$312,782.40

David Davidson Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $8.50

$7.94

$9.80

50 Day Range

MA: $8.53

$5.89

$14.73

2 Week Range

Now: $8.50

$5.80

$38.40

Volume

899,239 shs

Average Volume

398,183 shs

Market Capitalization

$82.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now